Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Return on Sales (2022 - 2025)

ARS Pharmaceuticals' Return on Sales history spans 4 years, with the latest figure at 1.48% for Q4 2025.

  • For Q4 2025, Return on Sales fell 208.0% year-over-year to 1.48%; the TTM value through Dec 2025 reached 2.13%, down 215.0%, while the annual FY2025 figure was 2.03%, 212.0% down from the prior year.
  • Return on Sales for Q4 2025 was 1.48% at ARS Pharmaceuticals, up from 1.64% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.6% in Q4 2024 and bottomed at 2424.57% in Q3 2023.
  • The 4-year median for Return on Sales is 20.33% (2022), against an average of 408.02%.
  • The largest annual shift saw Return on Sales tumbled -238949bps in 2023 before it soared 241405bps in 2024.
  • A 4-year view of Return on Sales shows it stood at 26.99% in 2022, then plummeted by -1310bps to 380.53% in 2023, then soared by 100bps to 0.6% in 2024, then tumbled by -346bps to 1.48% in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Return on Sales are 1.48% (Q4 2025), 1.64% (Q3 2025), and 3.03% (Q2 2025).